<DOC>
	<DOCNO>NCT01387932</DOCNO>
	<brief_summary>The purpose study evaluate overall survival patient treat HepaSphere/QuadraSphere compare conventional transarterial chemoembolization particle PVA .</brief_summary>
	<brief_title>HepaSphere/Quadrasphere Microspheres Delivery Doxorubicin Treatment Hepatocellular Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Ethiodized Oil</mesh_term>
	<criteria>Patients must meet follow inclusion criterion order enter study : 1 . Age 18 old 2 . Patient sign informed consent 3 . Patient must diagnosis hepatocellular cancer confirm least one following : i. Histological confirmation ii . Magnetic resonance imaging ( MRI ) result early enhancement delay enhancement washout least one solid liver lesion &gt; 1 cm . Patient must also evidence cirrhosis chronic hepatitis B. iii . Contrast enhance compute tomography ( CT ) early enhancement delay enhancement washout least one solid liver lesion &gt; 1cm . Patient must also evidence cirrhosis chronic hepatitis B. d. Patient must suitable treatment resection percutaneous ablation time study entry . Patients suitable ablation due lesion location may enrol e. Patient MUST meet least ONE follow criterion : . Stage ChildPugh B 7 ii . Recurrent HCC iii.Performance status ECOG 1 f. Patient life expectancy least 6 month g. Absence occlusive thrombus main portal trunk If patient meet follow criterion may enter study : 1 . Current previous treatment chemo radiation therapy sorafenib 2 . Previous treatment form transarterial embolization HCC 3 . Patients current history cancer except nonmelanomatous skin cancer 4 . Female patient pregnant , breastfeeding , premenopausal use effective method contraceptive 5 . Performance status ECOG &gt; 2 6 . ChildPugh score &gt; 7 7 . Active gastrointestinal bleeding 8 . Evidence uncorrectable bleed diathesis 9 . Extrahepatic spread HCC 10 . Total Bilirubin &gt; 3 mg/dL 11 . &gt; 50 % tumor involvement liver 12 . Infiltrative diffuse HCC 13 . Encephalopathy adequately control medically 14 . Presence ascites control medically 15 . Presence medically relevant localize systemic infection , hepatitis B , C , D , E G 16 . Any contraindication MRI ( eg . metallic implant ) 17 . Allergy contrast medium manage prophylaxis 18 . Allergy iodized oil 19 . Any contraindication arteriography 20 . Any contraindication doxorubicin administration , include follow : . White Blood Cell count ( WBC ) &lt; 3000 cells/mm₃ ii . Absolute Neutrophil &lt; 1500 cells/mm₃ iii . Cardiac ejection fraction &lt; 50 % iv . Other condition deem exclusionary physician u . Any contraindication hepatic embolization , include follow : i. Portosystemic shunt , arteriovenous shunt adequately close prior chemoembolization ii . Hepatofugal blood flow iii . Serum creatinine &gt; 2mg/dL iv . Uncorrectable impaired clot 1 . Platelet &lt; 50,000/mm₃ 2. International Normalized Ratio ( INR ) &gt; 1.4 3 . Activated Prothrombin Time ( aPTT ) less 21 great 40 v. AST &gt; 5X upper limit normal lab vi . ALT &gt; 5X upper limit normal lab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>TACE</keyword>
	<keyword>HepaSphere Microspheres</keyword>
	<keyword>QuadraSphere Microspheres</keyword>
	<keyword>Doxorubicin</keyword>
</DOC>